Últimas noticias sobre Merus (NASDAQ:MRUS) Bolsa

Merus

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Merus NV

Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) shares are trading higher Friday after the company reported promising interim results from its ongoing phase 2 trial evaluating petosemtamab in combination with pembrolizumab for <a href="https://www.benzinga.com/pressreleases/25/05/g45576972/merus-petosemtamab-with-pembrolizumab-interim-data-demonstrates-robust-efficacy-and-durability-in-">head and neck cancer.</a>
What To Know: The data, which will be formally presented at the 2025 ASCO Annual Meeting, showed a 63% overall response rate and a 79% 12-month overall survival rate among 43 evaluable patients with PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma.
The trial also reported a median progression-free survival of nine months, with six patients achieving complete responses and 21 showing partial responses. Importantly, no significant overlapping toxicities were observed in the treatment combination, which was generally well tolerated. Merus noted that 14 responders remained on therapy at the time of the Feb. 27 2025 data cutoff.
Analysts Weigh In: Needham raised its price target on Merus from $75 to $88, stating the updated data meaningfully de-risk the ongoing phase 3 trials. BMO Capital also raised its target from $96 to $110.
Topline data from one or both of the ongoing phase 3 studies are expected in 2026. 
MRUS Price Action: Merus shares were up 34.9% at $56.11 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45592743/stocks-bitcoin-fall-on-trumps-tariff-threats-gold-rallies-whats-driving-markets-friday">Stocks, Bitcoin Fall On Trump&#8217;s Tariff Threats, Gold Rallies: What&#8217;s Driving Markets Friday? </a></li>
</ul>
Image Via Shutterstock.

News

Movers

MRUS

Merus Stock Surges Over 35% On Strong Phase 2 Cancer Trial Results: What's Going On?

WIIM

Merus shares are trading higher after the company reported interim clinical data form the ongoing phase 2 trial of petosemtamab in combination with pembrolizumab. Multiple analysts raised their price targets on the stock.

BMO Capital analyst Evan David Seigerman maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Outperform and raises the price target from $96 to $110.

Price Target

Analyst Ratings

BMO Capital Maintains Outperform on Merus, Raises Price Target to $110

U.S. stocks were lower, with the Dow Jones index falling around 300 points on Friday.
Shares of Frontline plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) rose during Friday's session <a href="https://www.benzinga.com/quote/FRO/earnings">following first-quarter results</a>.
The company reported revenue of $427.9 million, surpassing the $264.2 million consensus. Adjusted EPS declined to 18 cents from 62 cents a year ago, missing the consensus of 23 cents.
Frontline shares gained 3.7% to $17.81 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) shares jumped 30% to $54.04 as the company disclosed interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) rose 24.7% to $34.40.</li>
<li>Centrus Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEU#NYSE">LEU</a>) gained 23.4% to $114.98.</li>
<li>Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) rose 23.1% to $49.03 after Wedbush raised its price target on the stock from $45 to $55 and maintained an Outperform rating.</li>
<li>Centrus Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEU#NYSE">LEU</a>) gained 23.1% to $114.80.</li>
<li>Uranium Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UEC#NYSE">UEC</a>) gained 19.2% to $6.15.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) shares gained 16% to $29.36.</li>
<li>NexGen Energy Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXE#NYSE">NXE</a>) rose 11.6% to $6.07.</li>
<li>Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) gained 8.8% to $724.54 after the company reported better-than-expected third-quarter financial results and raised guidance.</li>
<li>Cameco Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>) rose 8.2% to $57.13.</li>
<li>BWX Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>) gained 6.5% to $114.70.</li>
<li>Fluor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) rose 5.4% to $39.61.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45585296/jim-cramer-says-medical-properties-trust-has-too-much-risk-likes-this-industrial-stock">Jim Cramer Says Medical Properties Trust Has &#8216;Too Much Risk,&#8217; Likes This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Markets

Trading Ideas

BWXT

INTU

Nuveen Arizona Dividend Advantage Municipal Funds 3

OKLO

Frontline, Merus, Intuit And Other Big Stocks Moving Higher On Friday

Merus shares are trading higher after Needham raised its price target on the stock from $75 to $88.

Needham analyst Ami Fadia maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and raises the price target from $75 to $88.

Needham Maintains Buy on Merus, Raises Price Target to $88

-&nbsp; 63% response rate observed among 43 evaluable patients
-&nbsp; 79% overall survival rate at 12-months; 9 months median progression-free survival
-&nbsp; Conference Call on Thursday, May 22 at 5:30 p.m. ET &nbsp;
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=9FhYyVwI9DsnInrbxOt--inJgjOKfmMbph8kfn71rg_QOcr1YnuZK2hzrUydrWlBOD1YgWDc-HEZ2Du9ltkH1g==">Merus N.V.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics&#xAE;, Triclonics&#xAE; and ADClonics&#xAE;), today announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These data will be presented by Dr. Carla M. L. van Herpen M.D. Ph.D., Radboud University Medical Center, Nijmegen, Netherlands at the 2025 American Society of Clinical Oncology&#xAE; (ASCO&#xAE;) Annual Meeting on Monday, June 2 at 9 a.m. - 12:00 p.m. CT.

Biotech

General

Merus Reports Interim Phase 2 Data Showing 63% Response Rate And 79% 12-Month Overall Survival For Petosemtamab Plus Pembrolizumab In Ongoing Trial, To Be Presented At ASCO 2025 With Conference Call Scheduled For May 22

Needham analyst Ami Fadia reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $75 price target.

Reiteration

Needham Reiterates Buy on Merus, Maintains $75 Price Target

<a href="https://www.globenewswire.com/Tracker?data=1Cv5vc6xPugdycgEI5g5MdjtOphqPViQBh2de9Wew2xQaCN7hVFga3quhCMOlC-V5wWvMzxJvQZavTaoOXF6bg==">Merus N.V.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) ("Merus", "the Company", "we", or "our"), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics&#xAE;, Triclonics&#xAE; and ADClonics&#xAE;), today announced publication on the mechanism of action of petosemtamab, a bispecific antibody targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G (LGR5), in the scientific journal "Cancers", a MDPI publication, available <a href="https://www.globenewswire.com/Tracker?data=qDy227Jlbf1q1FH5Gxy-pD1yN8G32hMajPBa7ZAAO61n2po-XuClGyspYfkeqMv_Yt_DqAC3_Jcym2YqyszV_3-VsruA190TW6MqqQ6agkc=">here</a>.

Merus Announces Publication On Mechanism Of Action Of Petosemtamab, Bispecific Antibody Targeting EGFR And LGR5, In Scientific Journal "Cancers"

Wells Fargo analyst Eva Fortea Verdejo maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Overweight and lowers the price target from $91 to $89.

Wells Fargo Maintains Overweight on Merus, Lowers Price Target to $89

Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.10) by 27.27 percent. This is a 137.29 percent decrease over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $26.49 million which beat the analyst consensus estimate of $7.82 million by 238.85 percent. This is a 235.76 percent increase over sales of $7.89 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Merus Q1 EPS $(1.40) Misses $(1.10) Estimate, Sales $26.49M Beat $7.82M Estimate

- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation &nbsp;
- Conference call on&nbsp;Thursday, May 22&nbsp;at&nbsp;5:30 p.m. ET&nbsp;to discuss full ASCO&#xAE;&nbsp;data set
UTRECHT, The Netherlands&nbsp;and&nbsp;CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=yI2ecVsdRdXGdF2kI9WTwgqSchuYceNZul-sZuLiDMAEyEDBbIn5uDoCY8xIDJxN6qJWid8zPIakPcw51WnyrA==">Merus</a> N.V.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics&#xAE;, Triclonics&#xAE;&nbsp;and ADClonics&#xAE;), today announced the acceptance of an abstract for presentation at the 2025&nbsp;American Society of Clinical Oncology&#xAE;&nbsp;(ASCO&#xAE;) Annual Meeting, being held in&nbsp;Chicago, Illinois&nbsp;on&nbsp;May 30- June 3, 2025.
An updated analysis of the interim clinical data from the phase 2 trial of petosemtamab with pembrolizumab as 1L treatment of PD-L1+ recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC) will be presented in a poster at 2025 ASCO&#xAE;. The presentation will include data on the entire 45 patient dataset and follows the early clinical efficacy and encouraging safety data previously presented at 2024 ASCO&#xAE;.

Merus Says Petosemtamab In Combination With Pembrolizumab In 1L PD-L1+ R/M HNSCC Interim Clinical Data Selected For Poster Presentation At 2025 ASCO Annual Meeting

Needham analyst Ami Fadia reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $83 price target.

Needham Reiterates Buy on Merus, Maintains $83 Price Target

Guggenheim analyst Michael Schmidt reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $109 price target.

Guggenheim Reiterates Buy on Merus, Maintains $109 Price Target

B of A Securities analyst Tazeen Ahmad maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and lowers the price target from $73 to $70.

B of A Securities Maintains Buy on Merus, Lowers Price Target to $70

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $85 price target.

HC Wainwright & Co. Reiterates Buy on Merus, Maintains $85 Price Target

Needham analyst Ami Fadia maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and lowers the price target from $85 to $83.

Needham Maintains Buy on Merus, Lowers Price Target to $83

Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) reported quarterly losses of $(3.35) per share which beat the analyst consensus estimate of $(3.80) by 11.84 percent. The company reported quarterly sales of $36.133 which missed the analyst consensus estimate of $38.544 million by 100.00 percent.

Merus FY 2024 GAAP EPS $(3.35) Beats $(3.80) Estimate, Sales $36.133 Miss $38.544M Estimate

Shares of Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) are trading higher Tuesday after the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to <a href="https://www.benzinga.com/25/01/42961654/whats-going-on-with-merus-stock-monday">petosemtamab in combination with pembrolizumab.</a>
What To Know: The designation applies to the first-line treatment of adult patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma (r/m HNSCC) with a combined positive score of at least 1.
This marks the second BTD for petosemtamab, following an earlier designation for patients with r/m HNSCC whose disease had progressed after treatment with platinum-based chemotherapy and an anti-PD-1 antibody. The new designation is based on updated data from an ongoing phase 1/2 clinical trial, which initially showed a 67% response rate among 24 evaluable patients.
Breakthrough Therapy designation is intended to expedite the development and review of drugs that show substantial improvement over existing treatments for serious conditions. This status will allow Merus to work closely with the FDA, accelerating regulatory discussions and potentially leading to a faster approval process. 
MRUS Price Action: Merus shares were up 5.40% at $42.37 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021825&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="527" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18134832/Screenshot-2025-02-18-at-13.47.54-1024x527.png" alt="" class="wp-image-787550" style="width:476px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18134832/Screenshot-2025-02-18-at-13.47.54-1024x527.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18134832/Screenshot-2025-02-18-at-13.47.54-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18134832/Screenshot-2025-02-18-at-13.47.54-768x395.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18134832/Screenshot-2025-02-18-at-13.47.54.png 1522w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/02/43761300/intel-could-be-split-in-two-as-broadcom-and-tsmc-explore-deals-trump-white-house-resists-foreign-ownership-report">Intel Could Be Split In Two As Broadcom And TSMC Explore Deals, Trump White House Resists Foreign Ownership: Report</a></li>
</ul>
Image via Shutterstock.

Comments

Merus

Noticias

Últimas noticias sobre Merus (NASDAQ:MRUS) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL